Home
Resources
Diseases
Training
SYSVAC
About
Registry
E-learning courses
News
Events
Network
Vision and Mission
Steering Committee
Map
Meetings
Join us
Home
Resources
Resources
Selected
COVID-19
Poliomyelitis
NITAG documentation
2021
Clear all
Type of publications
NITAG documentation
(166)
SAGE documentation
(4)
Scientific publications
(1)
Systematic reviews (SYSVAC)
(230)
Topics
Agenda & Minutes
(2)
Background paper
(27)
Recommendation
(137)
Available to download in languages
English (EN)
(113)
French (FR)
(37)
Spanish (ES)
(12)
German (DE)
(7)
Swedish (SV)
(1)
Regions
Africa
(18)
Americas
(61)
Europe
(74)
South-East Asia
(2)
Western Pacific
(11)
Countries
Diseases
COVID-19
(164)
Poliomyelitis
(2)
Ebola
(1)
Hepatitis B
(1)
Herpes zoster
(1)
Influenza
(5)
Pneumococcal disease
(1)
Rotavirus
(3)
Varicella
(1)
Vaccine topics
Target population
Adults
(3)
Children
(3)
Older adults
(1)
Pregnant women
(4)
Risk group
(2)
Publication date
2021
(166)
2024
(2)
2023
(23)
2022
(81)
2020
(84)
2019
(3)
2018
(3)
2017
(6)
2016
(6)
2015
(1)
2014
(2)
2010
(3)
2009
(1)
2000
(1)
166 results found
2021
∙
JCVI, Public Health England
JCVI statement on use of the AstraZeneca COVID-19 vaccine: 7 April 2021
2021
∙
ATAGI
Joint statement on COVID-19 AstraZeneca vaccine advice from ATAGI - 20 May, 2021
2021
∙
ACIP
Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Janssen COVID-19 Vaccine
2021
Mandatory vaccination of healthcare personnel
2021
∙
Haute Autorité de Santé, Commission Technique des Vaccinations
Modification of the vaccine schedule against SARS-CoV-2 in the new epidemic context
2021
∙
NACI
NACI has updated its recommendations on the use of COVID-19 vaccines to include advice on the use of the Janssen COVID-19 vaccine - May 3, 2021
2021
∙
NACI
NACI issues updated recommendation on the use of mRNA COVID-19 vaccines in adolescents 12 to 17 years of age - 27 August, 2021
2021
∙
NACI
NACI rapid response: Additional dose of COVID-19 vaccine in immunocompromised individuals following 1- or 2- dose primary series - 10 September, 2021
2021
∙
NACI
NACI rapid response: Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada
2021
∙
NACI
NACI Rapid Response: Interchangeability of Authorized COVID-19 Vaccines - 01 June 2021
Home
Resources
Diseases
Training
SYSVAC
News
Events
Network
Sign in / Register